Scope and Claim Analysis for US Patent 11,324,751 (Paliperidone Palmitate 6-Month Extended-Release Injectable): What the Claims Cover, What They Don’t, and How to Map the Competitive IP Landscape
US Patent 11,324,751 is a method-of-administration patent for paliperidone palmitate 6‑month extended-release injectable suspension (PP6M). The enforceable claim scope centers on the timing and dosing continuity of a second 6‑month dose following a first PP6M dose, with an explicit no-intervening-dose requirement, limited to deltoid or gluteal intramuscular administration, and bounded by specific dose strengths and formulation concentration ranges of PP6M.
What does US 11,324,751 claim protect in plain terms?
Core protection target: re-starting or continuing maintenance PP6M dosing after the first PP6M injection by giving a second injection near the six-month mark (within a defined “dosing window”) while ensuring no paliperidone palmitate intervening dose occurs.
What makes it distinct: the patent’s novelty is not the generic “administer PP6M every six months,” but the combination of:
- Exact acceptable timing window relative to six months after dose 1
- No intervening paliperidone palmitate dose between dose 1 and dose 2
- Injection sites restricted to deltoid or gluteal muscle
- Dose amount restricted (about 1092 mg in claim 1 branch, about 1560 mg in claim 10 branch)
- Formulation concentration band restricted (PP6M contains about 280–350 mg/mL paliperidone palmitate) and, in dependent claims, specific formulation ranges (wetting agent, buffers, suspending agent) such as polysorbate 20 and PEG 4000 and pH 6.0–8.0
How broad are the independent claims of US 11,324,751 (claim 1 and claim 10)?
Claim 1 (structured elements):
- Patient needs treatment for psychosis spectrum indications, including schizophrenia, schizoaffective disorder, schizophreniform disorder, or bipolar disorder.
- Patient already received a first PP6M dose.
- Second PP6M dose is administered:
- to deltoid or gluteal muscle
- within a window: up to 2 weeks before or 3 weeks after the time that is six months after first dose
- and such that patient has not missed a dose based on the regimen
- No intervening dose of paliperidone palmitate between dose 1 and dose 2.
- Dose strength: first and second doses each comprise about 1092 mg paliperidone palmitate.
- PP6M formulation: paliperidone palmitate concentration about 280 mg/mL to about 350 mg/mL.
Claim 10 mirrors claim 1 but changes key numeric dosing elements:
- Dose strength: about 1560 mg paliperidone palmitate for first and second doses.
Practical scope summary
- Act of infringement is tied to administering PP6M under the claimed treatment schedule plus dose strength selection.
- The formulation concentration range is written into the method claim, so a generic/label-compliant schedule may still avoid infringement if the competitor’s PP6M product is outside the stated 280–350 mg/mL band (or outside dependent formulation parameters if those dependent claims are asserted).
What are the key claim limitations that constrain infringement risk?
1) Timing window relative to “six months after dose 1”
Claim 1/10 requires the second dose be within:
- -2 weeks to +3 weeks around six months after administration of dose 1.
This is a narrow, regimen-specific window. A provider who administers outside that window and documents a “missed dose” scenario could avoid meeting the timing element.
2) “No intervening dose of paliperidone palmitate”
The claims require there is no intervening dose of paliperidone palmitate between dose 1 and dose 2.
This matters in real-world switching and bridging:
- If a patient receives any paliperidone palmitate formulation in between (eg, monthly PP1M or other paliperidone palmitate depot products), the “no intervening dose” limitation is violated and the claim elements are not met.
3) Injection site restriction
The second dose must be administered to deltoid or gluteal muscle. Other anatomical sites would not satisfy this limitation.
4) Dose strength pairing
Both dose 1 and dose 2 must be the same dose strength:
- about 1092 mg (claim 1) or about 1560 mg (claim 10)
This makes the protection “pair-based.” A regimen where dose 2 differs from dose 1 could fall outside the literal scope.
5) Formulation concentration binding (method claim includes product definition)
The claims require that PP6M contains:
- about 280–350 mg/mL paliperidone palmitate
Dependent claims further define composition elements, including wetting agent and suspending agent, and pH.
How do dependent claims 2–9 and 11–18 expand or narrow scope?
Steady state plasma condition (claim 2, claim 18)
Dependent claims add:
- Patient has a steady state paliperidone plasma concentration at time of first dose.
This constrains the patient population. It also introduces an evidentiary/clinical condition often tied to loading and prior exposure. If a competitor scenario does not satisfy “steady state,” these dependent claims are easier to avoid.
Indication narrowing (claim 3, claim 11)
Both claims narrow:
- schizophrenia specifically
This is narrower than the independent claim’s broader list.
Gluteal-only version (claim 4, claim 12)
Adds:
- both doses administered to gluteal muscle (not deltoid)
Formulation composition banding (claim 5/14/17 and claim 6/15/16)
These dependent claims impose formulation specificity.
Claim 5 / 14:
- Wetting agent: ~8–12 mg/mL
- Suspending agent: ~65–85 mg/mL
- Buffers: “one or more buffering agents”
- Water to 100%
Claim 6 / 15:
Claim 7 / 16:
- buffering agents specifically include:
- citric acid monohydrate
- sodium dihydrogen phosphate monohydrate
- disodium hydrogen phosphate anhydrous
- sodium hydroxide
Claim 8 / 17 provides a tighter “exemplary composition”:
- paliperidone palmitate: about 312 mg/mL
- wetting agent: about 10 mg/mL, where wetting agent is polysorbate 20
- suspending agent: about 75 mg/mL, where suspending agent is polyethylene glycol 4000
Composition numeric anchoring has a compliance impact
Because the dependent claims are formulation-specific, a formulation redesign that stays therapeutically equivalent but shifts:
- wetting agent concentration
- suspending agent concentration or identity
- pH
- paliperidone palmitate concentration outside the 280–350 mg/mL band
may be an IP design-around pathway, at least against dependent claims. Against independent claims, only the broader 280–350 mg/mL band is required.
What is the practical “infringement pathway” for a competitor using PP6M?
To fall within claim 1 or claim 10 literally, a challenger’s clinical protocol must simultaneously satisfy:
- Patient received a PP6M dose (dose 1 at the claimed strength)
- Second dose is given within the defined dosing window around six months
- No paliperidone palmitate intervening dose occurs between the first and second doses
- Injection site is deltoid or gluteal
- PP6M paliperidone palmitate concentration falls within 280–350 mg/mL
- For claim 1 or claim 10 respectively, the strength pair matches (about 1092 mg or about 1560 mg)
In practice, clinical practice patterns, missed-dose handling, and bridging regimens can create non-infringement for method claims if dosing intervals or intervening depot use diverge from the claim.
What claims do NOT appear to be covered by US 11,324,751 (scope exclusions)?
Based on the text provided, protection is limited to:
- administration of a second dose under the cited schedule after a first PP6M dose
- a six-month regimen anchored to dose 1 timing
- no intervening paliperidone palmitate dosing
- deltoid or gluteal administration
Not covered on the face of the claims:
- initiation dosing strategies before dose 1
- induction/loading regimens that occur prior to reaching a “first dose”
- switching schedules that involve an intervening paliperidone palmitate product
- daily/oral paliperidone regimens
- other anatomical sites
- dosing beyond the second-dose event described (the claims are not written as indefinite maintenance continuation beyond dose 2)
How does US 11,324,751 compare with typical paliperidone palmitate patent themes (method, formulation, and regimen)?
Common landscape pattern for long-acting antipsychotics is that estates split across:
- molecule/primary composition
- delivery system formulation (suspension composition and particle behavior)
- manufacturing processes
- dosing regimens (timing windows, missed dose handling, bridging)
- indication-specific method-of-use
This patent’s claims combine regimen and product definition:
- regimen is the act: timing + injection site + continuity (“no intervening dose”)
- product definition is included: paliperidone concentration band and dependent formulation parameters (wetting agent, buffer identity, suspending agent, pH)
That structure tends to create a stronger enforcement position against “label-based” maintenance schedules for PP6M and against close formulation copies that remain in the same concentration and excipient envelope.
What is the likely US claim strategy behind 11,324,751 (why the two dose strengths)?
The existence of two independent claim sets in your excerpt (1092 mg and 1560 mg) suggests:
- separate dosing strengths are used for different patient starting conditions or exposure levels
- the patent attempts to capture both “dose-size” maintenance continuations under the same timing logic
This reduces workarounds based purely on using the alternate PP6M strength for both injections.
How strong is this patent estate on “claim robustness” (drafting that supports enforceability)?
Strength indicators in the claim text:
- Objective dosing window: “up to two weeks before or three weeks after” six months is clear enough to support clinical administration evidence.
- Binary intervening-dose requirement: “no intervening dose” is a crisp fact pattern tied to pharmacy administration records and EHR/administration charts.
- Site specificity: deltoid and gluteal limits the claim to the labeled depot injection sites.
- Product concentration band in independent claims: ties method infringement to a formulation-defined PP6M product spec.
Areas that can weaken practical enforcement:
- dependent claims requiring “steady state paliperidone plasma concentration at time of first dose” can be harder to prove for typical chart-based infringement (though still usable where therapeutic drug monitoring or known loading leads to steady state).
- formulation concentration bands and excipient ranges shift with manufacturing changes; a competitor may attempt a small adjustment that stays safe and effective but avoids numerical thresholds.
What Orange Book status or Paragraph IV risk exists for US 11,324,751?
No Orange Book listing, related FDA product codes, or any litigation/ANDA details are provided in the prompt. As a result, a complete and accurate Orange Book status or Paragraph IV risk map cannot be produced from the information given here.
What generic entry risks exist for PP6M under this claim set?
The method claim design increases risk for generics that:
- seek to market a PP6M product that meets the paliperidone palmitate concentration range (280–350 mg/mL)
- follow label-consistent administration timing and missed-dose handling that falls inside “up to two weeks before or three weeks after six months”
- avoid bridging with any intervening paliperidone palmitate depot product between dose 1 and dose 2
Risk is reduced if a generic:
- changes the PP6M formulation to fall outside the concentration band or dependent excipient/pH parameters (where asserted)
- implements different missed-dose/continuation logic that falls outside the defined window or includes an intervening paliperidone palmitate depot dose (or otherwise changes the “no intervening dose” condition)
Because your claims are explicitly tied to the second-dose after first-dose within a regimen window, the “generic entry” risk is most acute when payer/provider administration adheres tightly to that window and continuity requirement.
What patent litigation affects or could affect enforcement of US 11,324,751?
No litigation docket, settlement, or PTAB/court history is included in the prompt. A complete and accurate litigation landscape analysis cannot be produced from the provided data.
Key Takeaways
- US 11,324,751 protects a specific maintenance PP6M second-dose administration regimen: deltoid or gluteal IM, given within -2 weeks/+3 weeks around six months after dose 1, with no intervening paliperidone palmitate dosing.
- Independent claim scope is further limited by dose strength pairing (about 1092 mg or about 1560 mg) and a PP6M paliperidone palmitate concentration band (280–350 mg/mL).
- Dependent claims add patient condition (“steady state at time of first dose”), indication narrowing (schizophrenia), and tight formulation parameters (wetting agent, buffers, suspending agent identity and ranges, and pH 6.0–8.0).
- Enforceability in practice will hinge on administration records and whether the competitor product meets the claimed formulation concentration and whether dosing continuity rules are satisfied.
FAQs
-
Does US 11,324,751 cover first-dose initiation with PP6M or only continuation after dose 1?
The claims are written around administering a second dose after a first PP6M dose.
-
What happens if a patient receives another paliperidone palmitate depot between dose 1 and dose 2?
The “no intervening dose of paliperidone palmitate” limitation would not be met.
-
Is the injection site limited for the second dose?
Yes. The second dose must be administered to deltoid or gluteal muscle (with dependent claims also limiting to gluteal).
-
How can formulation changes reduce exposure to dependent claims?
Dependent claims constrain wetting agent, suspending agent, specific buffer identities, and pH. Moving outside those numeric ranges or identities may avoid dependent-claim coverage.
-
Are both dose strengths covered by the patent claims?
Yes. The provided claim set includes separate independent claim coverage for approximately 1092 mg and approximately 1560 mg PP6M dosing pairs.
References
- United States Patent 11,324,751 (paliperidone palmitate 6-month extended-release injectable suspension; method of administering second PP6M dose within a dosing window; claims as provided).
